Press Release
<< Back
Same Facility Revenue Grows 8.3%
Increases 2012 Earnings Guidance to Range of
Revenue for the first nine months of 2012 was
"The operating leverage generated by this increase in same facility revenue, as well as our disciplined focus on improved operating productivity and efficiency, drove a 230 basis point increase in the same facility EBITDA margin, to 21.4% of same facility revenue from 19.1% for the third quarter of 2011. Adjusted consolidated EBITDA increased to
"Acadia produced net cash flow from continuing operations of
Acadia today increased its guidance for 2012 adjusted earnings per diluted share to a range of
Acadia will hold a conference call to discuss its second quarter financial results at 9:00 a.m. Eastern Time on
Risk Factors
This news release contains forward-looking statements. Generally words such as "may," "will," "should," "could," "anticipate," "expect," "intend," "estimate," "plan," "continue," and "believe" or the negative of or other variation on these and other similar expressions identify forward-looking statements. These forward-looking statements are made only as of the date of this news release. We do not undertake to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are based on current expectations and involve risks and uncertainties and our future results could differ significantly from those expressed or implied by our forward-looking statements. Factors that may cause actual results to differ materially include, without limitation, (i) Acadia's ability to complete acquisitions and successfully integrate the operations of the acquired facilities; (ii) Acadia's ability to add beds, expand services, enhance marketing programs and improve efficiencies at its facilities; (iii) potential reductions in payments received by Acadia from the government and third-party payors; (iv) the risk that Acadia may not generate sufficient cash from operations to service its debt and meet its working capital and capital expenditure requirements; and (v) potential operating difficulties, client preferences, changes in competition and general economic or industry conditions that may prevent Acadia from realizing the expected benefits of its business strategy. These factors and others are more fully described in Acadia's periodic reports and other filings with the
About Acadia
Acadia is a provider of inpatient behavioral healthcare services. Acadia operates a network of 33 behavioral health facilities with over 2,400 licensed beds in 19 states. Acadia provides psychiatric and chemical dependency services to its patients in a variety of settings, including inpatient psychiatric hospitals, residential treatment centers, outpatient clinics and therapeutic school-based programs.
Acadia Healthcare Company, Inc. | ||||||||||||||||||||
Consolidated Statements of Operations | ||||||||||||||||||||
(Unaudited) | ||||||||||||||||||||
Three Months Ended |
Nine Months Ended | |||||||||||||||||||
2012 | 2011 | 2012 | 2011 | |||||||||||||||||
(in thousands, except per share amounts) | ||||||||||||||||||||
Revenue before provision for doubtful accounts | $ | 104,618 | $ | 61,385 | $ | 298,638 | $ | 142,797 | ||||||||||||
Provision for doubtful accounts | (1,502 | ) | (663 | ) | (5,429 | ) | (1,654 | ) | ||||||||||||
Revenue | 103,116 | 60,722 | 293,209 | 141,143 | ||||||||||||||||
Salaries, wages and benefits (including equity-based compensation expense of $521, $0, $1,691 and $19,843, respectively) | 59,888 | 38,422 | 173,590 | 108,158 | ||||||||||||||||
Professional fees | 4,690 | 2,302 | 13,521 | 5,018 | ||||||||||||||||
Supplies | 4,831 | 3,398 | 14,148 | 7,645 | ||||||||||||||||
Rents and leases | 1,775 | 1,591 | 6,244 | 3,576 | ||||||||||||||||
Other operating expenses | 11,380 | 4,915 | 30,768 | 12,760 | ||||||||||||||||
Depreciation and amortization | 2,076 | 909 | 5,332 | 3,108 | ||||||||||||||||
Interest expense, net | 7,433 | 1,928 | 22,186 | 4,143 | ||||||||||||||||
Sponsor management fees | - | 545 | - | 1,135 | ||||||||||||||||
Transaction-related expenses | 732 | 2,233 | 2,097 | 10,595 | ||||||||||||||||
Total expenses | 92,805 | 56,243 | 267,886 | 156,138 | ||||||||||||||||
Income (loss) from continuing operations before income taxes | 10,311 | 4,479 | 25,323 | (14,995 | ) | |||||||||||||||
Provision for income taxes | 3,723 | 908 | 9,307 | 3,426 | ||||||||||||||||
Income (loss) from continuing operations | 6,588 | 3,571 | 16,016 | (18,421 | ) | |||||||||||||||
(Loss) income from discontinued operations, net of income taxes | (138 | ) | (448 | ) | 22 | (562 | ) | |||||||||||||
Net income (loss) | $ | 6,450 | $ | 3,123 | $ | 16,038 | $ | (18,983 | ) | |||||||||||
Basic earnings per share: | ||||||||||||||||||||
Income (loss) from continuing operations | $ | 0.16 | $ | 0.20 | $ | 0.44 | $ | (1.05 | ) | |||||||||||
(Loss) income from discontinued operations | $ | (0.01 | ) | $ | (0.02 | ) | $ | - | $ | (0.03 | ) | |||||||||
Net income (loss) | $ | 0.15 | $ | 0.18 | $ | 0.44 | $ | (1.08 | ) | |||||||||||
Diluted earnings per share: | ||||||||||||||||||||
Income (loss) from continuing operations | $ | 0.16 | $ | 0.20 | $ | 0.43 | $ | (1.05 | ) | |||||||||||
(Loss) income from discontinued operations | $ | (0.01 | ) | $ | (0.02 | ) | $ | - | $ | (0.03 | ) | |||||||||
Net income (loss) | $ | 0.15 | $ | 0.18 | $ | 0.43 | $ | (1.08 | ) | |||||||||||
Weighted-average shares outstanding: | ||||||||||||||||||||
Basic | 41,757 | 17,633 | 36,795 | 17,633 | ||||||||||||||||
Diluted | 41,991 | 17,633 | 37,006 | 17,633 | ||||||||||||||||
Acadia Healthcare Company, Inc. | ||||||||||
Consolidated Balance Sheets | ||||||||||
(Unaudited) | ||||||||||
September 30, |
December 31, | |||||||||
(In thousands, except share and per share amounts) | ||||||||||
ASSETS | ||||||||||
Current assets: | ||||||||||
Cash and cash equivalents | $ | 11,719 | $ | 61,118 | ||||||
Accounts receivable, net of allowance for doubtful accounts of $6,581 and $2,424, respectively |
54,777 | 35,127 | ||||||||
Deferred tax asset | 5,230 | 6,239 | ||||||||
Other current assets | 15,305 | 10,121 | ||||||||
Total current assets | 87,031 | 112,605 | ||||||||
Property and equipment, net | 155,188 | 82,972 | ||||||||
Goodwill | 334,622 | 186,815 | ||||||||
Intangible assets, net | 12,534 | 8,232 | ||||||||
Deferred tax asset - noncurrent | - | 6,006 | ||||||||
Other assets | 14,383 | 16,366 | ||||||||
Total assets | $ | 603,758 | $ | 412,996 | ||||||
LIABILITIES AND EQUITY | ||||||||||
Current liabilities: | ||||||||||
Current portion of long-term debt | $ | 12,000 | $ | 6,750 | ||||||
Accounts payable | 13,323 | 8,642 | ||||||||
Accrued salaries and benefits | 19,125 | 16,195 | ||||||||
Other accrued liabilities | 13,374 | 9,081 | ||||||||
Total current liabilities | 57,822 | 40,668 | ||||||||
Long-term debt | 284,632 | 270,709 | ||||||||
Deferred tax liability - noncurrent | 1,167 | - | ||||||||
Other liabilities | 6,574 | 5,254 | ||||||||
Total liabilities | 350,195 | 316,631 | ||||||||
Equity: | ||||||||||
Common stock, $0.01 par value; 90,000,000 shares authorized; 41,773,053 and 32,115,929 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively | 418 | 321 | ||||||||
Additional paid-in capital | 281,687 | 140,624 | ||||||||
Accumulated deficit | (28,542 | ) | (44,580 | ) | ||||||
Total equity | 253,563 | 96,365 | ||||||||
Total liabilities and equity | $ | 603,758 | $ | 412,996 | ||||||
Acadia Healthcare Company, Inc. | ||||||||||
Consolidated Statements of Cash Flows | ||||||||||
(Unaudited) | ||||||||||
Nine Months Ended September 30, | ||||||||||
2012 | 2011 | |||||||||
(In thousands) | ||||||||||
Operating activities: | ||||||||||
Net income (loss) | $ | 16,038 | $ | (18,983 | ) | |||||
Adjustments to reconcile net income (loss) to net cash provided by continuing operating activities: |
||||||||||
Depreciation and amortization | 5,332 | 3,108 | ||||||||
Provision for doubtful accounts | 5,429 | 1,654 | ||||||||
Amortization of debt issuance costs | 1,869 | 684 | ||||||||
Equity-based compensation expense | 1,691 | 19,843 | ||||||||
Deferred income tax expense (benefit) | 8,138 | (109 | ) | |||||||
Other | (9 | ) | (170 | ) | ||||||
(Income) loss from discontinued operations, net of taxes | (22 | ) | 562 | |||||||
Change in operating assets and liabilities, net of effect of acquisitions: | ||||||||||
Accounts receivable | (19,026 | ) | (4,078 | ) | ||||||
Other current assets | (3,677 | ) | (618 | ) | ||||||
Other assets | 1,029 | - | ||||||||
Accounts payable and other accrued liabilities | 4,817 | 6,208 | ||||||||
Accrued salaries and benefits | 527 | 107 | ||||||||
Other liabilities | 1,527 | 217 | ||||||||
Net cash provided by continuing operating activities | 23,663 | 8,425 | ||||||||
Net cash used in discontinued operating activities | (328 | ) | (856 | ) | ||||||
Net cash provided by operating activities | 23,335 | 7,569 | ||||||||
Investing activities: | ||||||||||
Cash paid for acquisitions, net of cash acquired | (165,981 | ) | (178,014 | ) | ||||||
Cash paid for capital expenditures | (14,511 | ) | (6,777 | ) | ||||||
Cash paid for real estate acquisitions | (50,745 | ) | (2,150 | ) | ||||||
Other | 1,231 | (646 | ) | |||||||
Net cash used in continuing investing activities | (230,006 | ) | (187,587 | ) | ||||||
Net cash used in discontinued investing activities | - | (230 | ) | |||||||
Net cash used in investing activities | (230,006 | ) | (187,817 | ) | ||||||
Financing activities: | ||||||||||
Borrowings on long-term debt | 25,000 | 135,000 | ||||||||
Net increase in revolving credit facility | - | 6,500 | ||||||||
Principal payments on long-term debt | (6,000 | ) | (3,375 | ) | ||||||
Repayment of long-term debt | - | (9,984 | ) | |||||||
Payment of debt issuance costs | (1,197 | ) | (5,907 | ) | ||||||
Issuance of common stock | 138,954 | - | ||||||||
Proceeds from stock option exercises | 515 | - | ||||||||
Contribution from Holdings | - | 51,029 | ||||||||
Distributions to equity holders | - | (375 | ) | |||||||
Net cash provided by financing activities | 157,272 | 172,888 | ||||||||
Net decrease in cash and cash equivalents | (49,399 | ) | (7,360 | ) | ||||||
Cash and cash equivalents at beginning of the period | 61,118 | 8,614 | ||||||||
Cash and cash equivalents at end of the period | $ | 11,719 | $ | 1,254 | ||||||
Effect of acquisitions: | ||||||||||
Assets acquired, excluding cash | $ | 172,267 | $ | 213,073 | ||||||
Liabilities assumed | (6,286 | ) | (35,059 | ) | ||||||
Cash paid for acquisitions, net of cash acquired | $ | 165,981 | $ | 178,014 | ||||||
Acadia Healthcare Company, Inc. | ||||||||||||||||||||||||||||
Operating Statistics | ||||||||||||||||||||||||||||
(Unaudited) | ||||||||||||||||||||||||||||
(Revenue in thousands) | ||||||||||||||||||||||||||||
Three months ended September 30, | Nine months ended September 30, | |||||||||||||||||||||||||||
2012 | 2011 | % Change | 2012 | 2011 | % Change | |||||||||||||||||||||||
Same Facility Results | ||||||||||||||||||||||||||||
Revenue | $ | 65,773 | $ | 60,722 | 8.3 | % | $ | 153,173 | $ | 141,142 | 8.5 | % | ||||||||||||||||
Patient Days | 127,825 | 117,567 | 8.7 | % | 284,528 | 259,726 | 9.5 | % | ||||||||||||||||||||
Admissions | 3,542 | 2,953 | 19.9 | % | 9,020 | 7,666 | 17.7 | % | ||||||||||||||||||||
Average Length of Stay (a) | 36.1 | 39.8 | -9.4 | % | 31.5 | 33.9 | -6.9 | % | ||||||||||||||||||||
Revenue per Patient Day | $ | 515 | $ | 516 | -0.4 | % | $ | 538 | $ | 543 | -0.9 | % | ||||||||||||||||
EBITDA margin | 21.4 | % | 19.1 | % | 230 bps | 22.5 | % | 21.2 | % | 130 bps | ||||||||||||||||||
Total Facility Results | ||||||||||||||||||||||||||||
Revenue | $ | 102,816 | $ | 60,722 | 69.3 | % | $ | 292,869 | $ | 141,142 | 107.5 | % | ||||||||||||||||
Patient Days | 176,478 | 117,567 | 50.1 | % | 499,615 | 259,726 | 92.4 | % | ||||||||||||||||||||
Admissions | 7,737 | 2,953 | 162.0 | % | 21,908 | 7,666 | 185.8 | % | ||||||||||||||||||||
Average Length of Stay (a) | 22.8 | 39.8 | -42.7 | % | 22.8 | 33.9 | -32.7 | % | ||||||||||||||||||||
Revenue per Patient Day | $ | 583 | $ | 516 | 12.8 | % | $ | 586 | $ | 543 | 7.9 | % | ||||||||||||||||
EBITDA margin | 25.5 | % | 19.1 | % | 640 bps | 23.9 | % | 21.2 | % | 270 bps | ||||||||||||||||||
(a) Average length of stay is defined as patient days divided by admissions. | ||||||||||||||||||||||||||||
Acadia Healthcare Company, Inc. | ||||||||||||||||||
Reconciliation of Net Income (Loss) to Adjusted EBITDA | ||||||||||||||||||
(Unaudited) | ||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||
2012 | 2011 | 2012 | 2011 | |||||||||||||||
(in thousands) | ||||||||||||||||||
Net income (loss) | $ | 6,450 | $ | 3,123 | $ | 16,038 | $ | (18,983 | ) | |||||||||
Loss (income) from discontinued operations | 138 | 448 | (22 | ) | 562 | |||||||||||||
Provision for income taxes | 3,723 | 908 | 9,307 | 3,426 | ||||||||||||||
Interest expense, net | 7,433 | 1,928 | 22,186 | 4,143 | ||||||||||||||
Depreciation and amortization | 2,076 | 909 | 5,332 | 3,108 | ||||||||||||||
EBITDA | 19,820 | 7,316 | 52,841 | (7,744 | ) | |||||||||||||
Adjustments: | ||||||||||||||||||
Equity-based compensation expense (a) | 521 | - | 1,691 | 19,843 | ||||||||||||||
Transaction-related expenses (b) | 732 | 2,233 | 2,097 | 10,595 | ||||||||||||||
Sponsor management fees (c) | - | 545 | - | 1,135 | ||||||||||||||
Adjusted EBITDA | $ | 21,073 | $ | 10,094 | $ | 56,629 | $ | 23,829 | ||||||||||
See footnotes on page 10. | ||||||||||||||||||
Acadia Healthcare Company, Inc. | ||||||||||||||||||||
Reconciliation of Adjusted Income (Loss) from Continuing Operations to Income (Loss) from | ||||||||||||||||||||
Continuing Operations | ||||||||||||||||||||
(Unaudited) | ||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||
2012 | 2011 | 2012 | 2011 | |||||||||||||||||
(in thousands, except per share amounts) | ||||||||||||||||||||
Income (loss) from continuing operations | $ | 6,588 | $ | 3,571 | $ | 16,016 | $ | (18,421 | ) | |||||||||||
Provision for income taxes | 3,723 | 908 | 9,307 | 3,426 | ||||||||||||||||
Income (loss) from continuing operations before income taxes | 10,311 | 4,479 | 25,323 | (14,995 | ) | |||||||||||||||
Adjustments to income (loss) from continuing operations: | ||||||||||||||||||||
Transaction-related expenses (b) | 732 | 2,233 | 2,097 | 10,595 | ||||||||||||||||
Sponsor management fees (c) | - | 545 | - | 1,135 | ||||||||||||||||
Income tax provision reflecting tax effect of adjustments to income (loss) from continuing operations (d) | (3,987 | ) | (1,473 | ) | (10,091 | ) | (744 | ) | ||||||||||||
Adjusted income (loss) from continuing operations | $ | 7,056 | $ | 5,784 | $ | 17,329 | $ | (4,009 | ) | |||||||||||
Weighted-average shares outstanding - diluted | 41,991 | 17,633 | 37,006 | 17,633 | ||||||||||||||||
Adjusted income (loss) from continuing operations per diluted share | $ | 0.17 | $ | 0.33 | $ | 0.47 | $ | (0.23 | ) | |||||||||||
See footnotes on page 10. | ||||||||||||||||||||
Footnotes |
We have included certain financial measures in this press release, including EBITDA, Adjusted EBITDA and Adjusted income (loss) from continuing operations, which are "non-GAAP financial measures" as defined under the rules and regulations promulgated by the SEC. We define EBITDA as net income (loss) adjusted for loss (income) from discontinued operations, net interest expense, income tax provision and depreciation and amortization. We define Adjusted EBITDA as EBITDA adjusted for equity-based compensation expense, transaction-related expenses, and sponsor management fees. |
EBITDA, Adjusted EBITDA and Adjusted income (loss) from continuing operations are supplemental measures of our performance and are not required by, or presented in accordance with, generally accepted accounting principles in the United States ("GAAP"). EBITDA, Adjusted EBITDA and Adjusted income (loss) from continuing operations are not measures of our financial performance under GAAP and should not be considered as alternatives to net income or any other performance measures derived in accordance with GAAP or as an alternative to cash flow from operating activities as measures of our liquidity. Our measurements of EBITDA, Adjusted EBITDA and Adjusted income (loss) from continuing operations may not be comparable to similarly titled measures of other companies. We have included information concerning EBITDA, Adjusted EBITDA and Adjusted income (loss) from continuing operations in this press release because we believe that such information is used by certain investors as measures of a company's historical performance. We believe these measures are frequently used by securities analysts, investors and other interested parties in the evaluation of issuers of equity securities, many of which present EBITDA, Adjusted EBITDA and Adjusted income (loss) from continuing operations when reporting their results. Our presentation of EBITDA, Adjusted EBITDA and Adjusted income (loss) from continuing operations should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items. |
(a) Represents the equity-based compensation expense of Acadia. |
(b) Represents transaction-related expenses incurred by Acadia related primarily to the acquisitions of Youth and Family Centered Services, Inc. ("YFCS") in April 2011, PHC, Inc. ("PHC") in November 2011, three facilities from Haven Behavioral Healthcare Holdings, LLC (the "Haven Facilities") in March 2012 and Timberline Knolls, LLC ("Timberline Knolls") in August 2012. |
(c) Represents the management fees paid by Acadia to its equity sponsor prior to the termination of the professional services agreement between Acadia and its equity sponsor on November 1, 2011. |
(d) Represents the income tax provision adjusted to reflect the aggregate tax effect of the adjustments to income (loss) from continuing operations described above based on effective tax rates. |
Source:
Acadia Healthcare Company, Inc.
Brent Turner, 615-861-6000
President